You should not have to study biochemistry to understand what is in a product. But with NAD+, the name in the headline and the ingredient on the label may be different.
I would start with that simple question: what is this actually meant to contain?
A few names, in plain English
NAD+, short for nicotinamide adenine dinucleotide, helps cells carry out metabolic processes. It is a coenzyme, not a peptide.
NMN, or nicotinamide mononucleotide, is something the body can use to make NAD+. NR, nicotinamide riboside, is another starting ingredient in that process.
You may see NMN and NR called “precursors”. That means they are used to make something else. They are not simply alternative names for NAD+. [1]
What does the Australian guidance say?
The TGA’s guidance dated 12 August 2026 covers a particular category: medicines listed under section 26A of the Therapeutic Goods Act. NAD, NAD+ and NADH are not permitted ingredients in that category. NMN is permitted subject to requirements, and the permitted list includes other precursors such as nicotinamide riboside chloride. [1]
This is not a blanket rule about every therapeutic product or supply pathway. And being allowed as an ingredient is not proof of every advertised benefit. For these listed medicines, sponsors certify compliance; the TGA does not evaluate each product before listing it.
Start with the ingredient panel
A product promoted using NAD+ language might contain a precursor. The TGA says the name and overall presentation must not mislead people about ingredients or permitted uses. [1]
I think an ingredient-panel photograph and the exact product name make a better starting point for a pharmacist’s advice than a broad description such as “energy supplement”.
This article has not tested a bottle. Reading a label tells us what is declared, not independently what is in a batch.
A role in the body is not a guaranteed benefit from taking more
Understanding how a molecule works gives researchers a reason to investigate it. Showing that a particular product helps people feel or function better is another step.
That is where I want the conversation to go: was this product, taken this way, tested for the benefit being promised?
What I would ask
What exact ingredient and formulation is this? What is its Australian regulatory status? Does the research concern this product or a different one? What did people actually experience, and what remains uncertain?
Those questions let us stay interested without having to take every claim at face value.
Read the original source
- TGA: Making NAD, NAD+, NADH or NMN representations for listed medicines ↗12 August 2026 · Australian regulatory guidance; checked 26 September 2026. Its scope is section 26A listed medicines, not every therapeutic product or access pathway.